Cassidy remained undecided before a scheduled Senate committee vote

The White House has withdrawn Heidi Overton’s nomination to lead the Food and Drug Administration, a White House official told The Guardian. The move came a day before a Senate health committee vote, after Overton faced bipartisan questions about her willingness to break from Trump, particularly over his unsupported claims about the dangers of childhood vaccines.

Donald Trump nominated Overton, a physician, in August. The Guardian described her as a prominent abortion opponent who had spent most of her professional career working directly for Trump or conservative groups aligned with him. The Guardian reported that the nomination was seen as an effort to bring a stabilizing Trump loyalist to the FDA after a tumultuous year under Trump’s first FDA commissioner, Marty Makary.

Republican Sen. Bill Cassidy, a Louisiana doctor who chairs the Senate health committee, pressed Overton during a September hearing about scientific independence and her willingness to push back against Trump and Health Secretary Robert F Kennedy Jr, whom The Guardian described as a longtime vaccine critic.

On Tuesday, Cassidy said he remained undecided about Overton’s nomination ahead of the committee’s scheduled Wednesday vote. He had previously called Overton’s support for Trump’s plan to break up combination vaccines, including the measles, mumps and rubella shot, “almost disqualifying.”

To win confirmation, Overton would have needed the votes of all 12 Republicans on the Senate health, education, labor and pensions committee. Democrats hold 11 seats. Without support from the committee, Overton faced little chance of winning a full Senate vote on the chamber floor.

As head of the FDA, Overton would have overseen the agency that regulates medication abortions. Her policy positions placed her at the center of the confirmation debate.

In a 2023 policy brief for the conservative America First Policy Institute, Overton said Congress should strictly regulate the abortion pill mifepristone “to protect women and children.” She criticized federal policies that allow for the mailing of abortion pills and wrote that abortion “is corrosive to children, women, and society broadly.”

Reproductive Freedom for All celebrated the White House’s decision. Mini Timmaraju, the president and CEO of Reproductive Freedom for All, formerly Naral Pro-Choice America, said: “Heidi Overton posed a serious threat to the future of medication abortion access. Voters rejected that anti-abortion agenda nationwide, and our members kept the pressure on to tank her confirmation. If Republicans try to rush through another nominee who threatens our healthcare, we’re ready to keep fighting.”

Republicans were racing to try to confirm all of Trump’s current nominees before they handed over power to Senate Democrats in January.